EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database

Chengze Liang, Saifu Yin, Hao Zhang, Turun Song, Tao Lin

International Immunopharmacology · 2026-01 · 168 · 115751

DOI: 10.1016/j.intimp.2025.115751 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-01. Verfasst von Chengze Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; West China Medical School of Sichuan U…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adverse Drug Reaction Reporting Systems, Product Surveillance, Postmarketing, Complement Inactivating Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Sichuan University West China Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAdverse Drug Reaction Reporting SystemsProduct Surveillance, PostmarketingComplement Inactivating AgentsHumansPharmacovigilanceMaleFemaleDatabases, FactualAdultMiddle AgedAgedAdolescentYoung AdultChildUnited StatesChild, PreschoolInfantUnited States Food and Drug AdministrationAged, 80 and over

Stichwörter der Autor:innen

Complement C5 inhibitorEculizumabFDA adverse event reporting systemPharmacovigilance

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Inactivating Agents

Autor:innen und Institutionen

  • Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; West China Medical School of Sichuan University, Chengdu, Sichuan, China; Kidney Transplantation Center, Wes…
  • Department of Urology/ Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Kidney Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Organ Trans…

Förderung

  • Sichuan University West China Hospital

Zitieren

APA

Liang, C., Yin, S., Zhang, H., Song, T., & Lin, T. (2026). Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database. International Immunopharmacology, 168, 115751. https://doi.org/10.1016/j.intimp.2025.115751

Vancouver

Liang C, Yin S, Zhang H, Song T, Lin T. Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database. International Immunopharmacology. 2026;168:115751. doi:10.1016/j.intimp.2025.115751

BibTeX
@article{Liang2026,
  author = {Liang, Chengze and Yin, Saifu and Zhang, Hao and Song, Turun and Lin, Tao},
  title = {Evaluation of the post-marketing safety of eculizumab from 2007 to 2025: A real-world pharmacovigilance study and signal analysis based on the FAERS database},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {168},
  pages = {115751},
  doi = {10.1016/j.intimp.2025.115751}
}
Kostenlos starten →